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A B S T R A C T
Purpose
To evaluate the financial experiences of a racially and ethnically diverse cohort of long-term breast cancer
survivors (17% African American, 40% Latina) identified through population-based registries.
Methods
Longitudinal study of women diagnosed with nonmetastatic breast cancer in 2005 to 2007 and
reported to the SEER registries of metropolitan Los Angeles and Detroit. We surveyed 3,133
women approximately 9 months after diagnosis and 4 years later. Multivariable models evaluated
correlates of self-reported decline in financial status attributed to breast cancer and of experienc-
ing at least one type of privation (economically motivated treatment nonadherence and broader
hardships related to medical expenses).
Results
Among 1,502 patients responding to both surveys, median out-of-pocket expenses were
 $2,000; 17% of respondents reported spending  $5,000; 12% reported having medical debt
4 years postdiagnosis. Debt varied significantly by race: 9% of whites, 15% of blacks, 17% of
English-speaking Latinas, and 10% of Spanish-speaking Latinas reported debt (P  .03). Overall,
25% of women experienced financial decline at least partly attributed to breast cancer; Spanish-
speaking Latinas had significantly increased odds of this decline relative to whites (odds ratio [OR],
2.76; P  .006). At least one privation was experienced by 18% of the sample; blacks (OR, 2.6; P 
.001) and English-speaking Latinas (OR, 2.2; P  .02) were significantly more likely to have
experienced privation than whites.
Conclusion
Racial and ethnic minority patients appear most vulnerable to privations and financial decline
attributable to breast cancer, even after adjustment for income, education, and employment.
These findings should motivate efforts to control costs and ensure communication between
patients and providers regarding financial distress, particularly for vulnerable subgroups.
J Clin Oncol 32:1269-1276. © 2014 by American Society of Clinical Oncology
INTRODUCTION
Considerable attention has focused on the financial
burden of medical care,1,2 and experts have advo-
cated for further research to investigate both the
objective financial cost of cancer care and the sub-
jective experiences of patients relating to these
costs.3 Patients increasingly bear some of the cost of
treatment through rising insurance premiums, de-
ductibles, and copayments,4-6 and patients with can-
cer in particular have been shown to face higher
out-of-pocket expenses than patients with other
chronic conditions.7,8 Patients with cancer also face
challenges in maintaining employment-related in-
come to pay for these costs.9-12
Given the potential for both substantial ex-
penses and challenges to maintaining income, pa-
tients with cancer may be particularly vulnerable to
financial distress after diagnosis and treatment. In-
deed, patients with cancer are more than twice as
likely to file for bankruptcy as others,13 but less is
known about how patients with cancer finance ex-
penses or the privations they suffer as a result.14 In a
population-based study of colon cancer survivors,
38% reported accruing debt, selling or refinancing
their home, borrowing from friends or family, or
experiencing  20% income decline.15 Further re-
search is necessary to define the financial burden of
care for other types of cancer and to identify which
patients are most vulnerable.
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We evaluated the financial experiences of a diverse cohort of
breast cancer survivors identified through population-based registries
and how they varied by race/ethnicity. We specifically investigated
self-reported out-of-pocket medical expenses, how they financed
these expenses, their perceptions of their financial status, and the
privations they experienced in the currently challenging broader eco-
nomic environment. We also described these breast cancer survivors’
experiences with employment after diagnosis and treatment. Finally,
we evaluated whether certain racial/ethnic subgroups of long-term
breast cancer survivors were more vulnerable to financial distress.
METHODS
Study Sample
We conducted a longitudinal cohort study of women diagnosed with
breast cancer in metropolitan Los Angeles and Detroit. Patients age 20 to 79
years diagnosed with stage 0 to III breast cancer between June 2005 and
February 2007, as reported to the National Cancer Institute’s SEER
population-based program registries in those regions, were eligible for sam-
ple selection.
Patients were excluded if they had stage IV breast cancer or could not
complete a questionnaire in English or Spanish. Asian women in Los Angeles
were excluded because of enrollment in other studies. Latina (in Los Angeles)
and black (in both Los Angeles and Detroit) patients were oversampled to
ensure sufficient minority representation.
Questionnaire Design and Content
Questionnaires were based on existing literature, measures previously
developed to assess relevant constructs, and theoretical models. For the items
relating to financial experiences, we adapted questions previously utilized by
the Consumer Bankruptcy Project16; for items relating to employment and
insurance experiences, we adapted questions from surveys conducted by the
Bureau of Labor Statistics in the general population, and items previously
developed by labor economists for use in patients with cancer.17,18 We utilized
standard techniques of content validation,19 including systematic review by
design experts20-22 and pretesting with 40 patients in three waves, including 12
detailed cognitive interviews.23,24
Data Collection
After institutional review board approval, patients were identified via
rapid case ascertainment and surveyed a mean of 9 months after diagnosis, and
again approximately 4 years later. To encourage response, we provided a $10
cash incentive and used a modified Dillman method.25 All materials were sent
in English and Spanish to those with Spanish surnames.26 The response rate to
the baseline survey was 73%, and the response rate to the follow-up survey was
68%. Survey responses were combined into a single data set, into which clinical
data from SEER were merged. More details regarding the flow of patients into
the sample are provided in Appendix Fig A1, online only.
Measures
We included several measures of financial impact in the follow-up sur-
vey. First, we measured patients’ perceptions of whether, since diagnosis, they
were worse off financially (financial decline). Among those perceiving finan-
cial decline, we asked whether this was due to breast cancer. We dichotomized
responses for analysis (a little bit, somewhat, quite a bit, or very much versus
not at all). Those who indicated they were worse off because of breast cancer (a
little bit, somewhat, quite a bit, or very much) were considered to have had
financial decline attributed at least partly to breast cancer.
We also asked how much the respondent paid in total for out-of-pocket
medical expenses related to breast cancer, including copayments, hospital bills,
and medication costs, with categorical response options. We then asked how
they paid for out-of-pocket expenses and asked whether survivors currently
had debt from their breast cancer treatments.
We evaluated privations related to breast cancer by using two sets of
items in the follow-up survey. First, we evaluated economically motivated
treatment nonadherence by asking whether in the past 12 months survivors
had gone without medication, taken less than the fully prescribed amount of a
medication, missed a doctor’s appointment, or missed a mammogram be-
cause of cost. Second, we evaluated broader hardships related to the patient’s
medical expenses by asking whether, since breast cancer diagnosis, she or
anyone in her household had gone without health insurance, had utilities
turned off because of unpaid bills, or had to move out of their home because of
the respondent’s own personal medical expenses.
We also inquired regarding employment and insurance status in the
follow-up survey, including whether, since diagnosis, women perceived they
were worse off, and if so, if this was due to breast cancer. The follow-up survey
inquired whether survivors had worked for pay since diagnosis. Among those
who did, we asked how important it had been to avoid changing jobs because
of worry about losing health insurance, to keep working to keep health insur-
ance, or to get a new job in order to get health insurance (dichotomized for
analysis as at least a little important versus not at all important). Among those
working at any time since diagnosis, we asked whether they would look for a
new job if they could be assured of comparable benefits, had increased work
hours to cover breast cancer-related medical expenses, had decreased work
hours because of breast cancer-related health issues, or been denied job oppor-
tunities because of breast cancer. We also assessed the extent to which the costs
of prescription medications had been covered by health insurance in the past
12 months.
We defined four race/ethnic groups by using responses from the baseline
survey: non-Hispanic whites, non-Hispanic blacks, English-speaking Latinas
(ES-Latina), and Spanish-speaking Latinas (SS-Latina), using the Short Accul-
turation Scale for Hispanics to subdivide the latter two groups. Of note, the
three participants who identified as both black and Latina were coded as
Latina. We measured other pertinent sociodemographic factors in the baseline
survey: age, education, employment status at diagnosis, marital status, and
household income. Clinical factors measured in the baseline survey were
comorbidity, chemotherapy receipt, radiotherapy receipt, and surgery. SEER
records provided clinical stage, and the follow-up survey inquired about breast
cancer recurrence.
Analytic Approach
To allow statistical inferences to represent the original targeted popula-
tion, we applied complex survey weights to the calculation of percentages and
regression analyses. Design weights compensated for the oversampling of
minorities and disproportionate selection across SEER sites; nonresponse
weights compensated for the fact that women with certain characteristics were
not as likely to respond to the surveys at each time point, as described further in
the Data Supplement. Analyses were conducted by using SAS (SAS/STAT
User’s Guide, Version 9.2; SAS Institute, Cary, NC).
We compared self-reported financial and employment experiences of
survivors by race/ethnicity by using the 2 test, limiting analysis to those who
could be assigned to one of the four race/ethnic groups. We further con-
structed two adjusted logistic regression models to evaluate the correlates of
decline in financial status attributed to breast cancer, as well as of having
experienced at least one type of privation. Both models included the following
theoretically selected independent variables: age, race/ethnicity, education,
employment status at diagnosis, marital status, household income, comorbid-
ity, stage, chemotherapy receipt, radiotherapy receipt, surgery, breast cancer
recurrence, prescription drug coverage during survivorship, reduction in work
hours during survivorship, and geographic site. Although missing data for
most variables selected for model inclusion were less than 5%, income infor-
mation was missing for 18.9%, so we employed multiple imputation for
missing income data as described in the Data Supplement.
RESULTS
Of 3,133 women surveyed, 2,290 (73%) completed the baseline survey
and 1,536 (68%) completed the follow-up, of whom 1,502 could be
categorized for race/ethnicity. Table 1 reports the characteristics of
these 1,502 patients. The sample was diverse, with 17% black and 40%
Jagsi et al
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Latina. A total of 52% had stage 0 to I disease, 62% received breast-
conserving surgery, and 52% received chemotherapy.
Overall, 33% of respondents reported decline in financial status
since diagnosis. Of those, 77% felt this was at least partly because of
breast cancer (for a total of 25% reporting decline attributed at least
partly to breast cancer). As Figure 1A depicts, both the proportion
reporting decline in financial status (P  .001) and the proportion of
those who attributed this to breast cancer (P  .001) varied
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English-speaking Latina 191 19.5
Spanish-speaking Latina 203 20.4
Education
High school or less 557 42.1
Some college 510 31.5
College graduate or greater 411 24.4
Missing 24 2.0
Family income at baseline survey
 $50,000 637 44.0
$50,000 600 36.1
Missing or do not know 265 19.8
Marital status
Not married or partnered 635 42.0













Breast conservation 994 62.4
Mastectomy without reconstruction 269 21.4





Work status at diagnosis
Full time 651 42.4
Part time 196 13.1
Not working 643 43.3
Missing 12 1.2
Geographic site






















































































































Fig 1. Each bar depicts the percent of respondents who reported being worse
off since diagnosis; the blue portion indicates those who attributed this at least
partly to breast cancer. (A) The overall proportion of patients reporting decline in
financial status varied significantly by race/ethnicity (P  .001), as did the
proportion attributing decline at least partly to breast cancer (P  .001). (B) The
overall proportion reporting decline in employment status did not vary by
race/ethnicity (P  .23), but the proportion of those attributing the decline at least
partly to breast cancer did (P  .005). (C) The overall proportion reporting decline
in insurance status did not vary by race/ethnicity (P  .52), but the proportion of
those attributing it at least partly to breast cancer did (P  .006).
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significantly by race/ethnicity. Table 2 presents a multivariable logistic
regression model, in which SS-Latinas had significantly increased
odds of financial decline attributed to breast cancer, as did those with
age younger than 65, household income  $50,000 at diagnosis, part-
time employment at diagnosis, reduction in work hours, lack of sub-
stantial prescription drug coverage, breast cancer recurrence, and
chemotherapy receipt.
As shown in Table 3, the median out-of-pocket spending for
breast cancer medical expenses was  $2,000; 17% of respondents
spent  $5,000. A much lower proportion of SS-Latinas (57%) re-
ported being able to rely on income or savings than other groups (P 
.001). ES-Latinas were considerably more likely than other groups to
increase credit-card debt to finance their medical expenses (P  .03).
Blacks were more likely to report leaving medical bills unpaid (P 
Table 2. Multivariable Model of Reporting Decline in Financial Status
Attributed at Least Partly to Breast Cancer
Covariate
Worsening Financial Status
at Least Partly Due to
Breast Cancer (N  1,244)
OR 95% CI P
Site
Los Angeles (reference) 1.00
Detroit 1.07 0.72 to 1.61 .732
Age at diagnosis, years
 46 3.99 1.98 to 8.07  .001
46-55 3.25 1.68 to 6.28  .001




Black 0.87 0.52 to 1.44 .587
Latina, English-speaking 1.45 0.83 to 2.53 .190
Latina, Spanish-speaking 2.76 1.33 to 5.72 .006
Education
College graduate or greater 0.77 0.47 to 1.26 .300
Some college/technical school (reference) 1.00
High school graduate 0.81 0.48 to 1.38 .443
Less than high school 0.67 0.34 to 1.33 .255
Marital status
Married/partnered (reference) 1.00
Not married 1.25 0.82 to 1.90 .303
Household income
$50,000 (reference) 1.00
 $50,000 1.77 1.04 to 3.00 .034
Working at diagnosis
Not working (reference) 1.00
Part time 1.88 1.11 to 3.19 .019
Full time 1.11 0.70 to 1.75 .663
Reduction in work hours
No (reference) 1.00
Yes 1.68 1.02 to 2.78 .042
Prescriptions covered by health insurance
Completely (reference) 1.00
Mostly 1.09 0.64 to 1.85 .746
Partially 3.67 2.09 to 6.45  .001
Not covered 2.70 1.27 to 5.73 .010
Comorbidities
0 (reference) 1.00
1 0.84 0.56 to 1.25 .386
Stage of disease
3 1.92 0.98 to 3.76 .058
2 1.34 0.84 to 2.14 .216
1 (reference) 1.00
0 1.05 0.61 to 1.80 .869
Surgery
Lumpectomy (reference) 1.00
Mastectomy without reconstruction 0.62 0.33 to 1.17 .140
Mastectomy with reconstruction 1.00 0.53 to 1.87 .995
Chemotherapy
No (reference) 1.00
Yes 2.14 1.32 to 3.47 .002
Radiotherapy




Yes 2.44 1.17 to 5.06 .017
Abbreviation: OR, odds ratio.
















 $500 40 64 42 47 25  .001
$500-$2,000 25 20 20 30 28
$2,001-$5,000 18 7 17 16 24
$5,001-$10,000 10 6 12 4 14




savings 80 57 79 81 90  .001
Borrowed from family or
friends 7 10 8 9 4 .04
Borrowed against house 2 0 2 2 2 .41
Left some medical bills
unpaid 5 3 5 14 3  .001
Increased credit card




treatment 12 10 17 15 9 .03
Privations




medication 5 6 7 6 4 .08
Taking less than fully
prescribed amount 4 4 4 6 3 .01
Missing doctor’s





insurance 6 8 9 8 2  .001
Having utilities turned
off because of unpaid
bills 5 5 4 11 2  .001
Having to move out of
home because could
not afford to stay 4 5 6 6 2  .001
P values on the basis of comparison across the four race/ethnic groups by
using the weighted 2 test statistic.
†Totals do not sum to 100% because of rounding.
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.001). Minority respondents were more likely to borrow from family
or friends than whites (P  .04).
Twelve percent of respondents reported that they had medical
debt 4 years postdiagnosis. Debt varied significantly by race/ethnicity,
with 9% of whites, 15% of blacks, 17% of ES-Latinas, and 10% of
SS-Latinas reporting debt (P  .03). As also reported in Table 3,
minority respondents were more likely to report foregoing medical
care because of cost and other privations because of their medical
expenses. At least one privation was experienced by 18% of the sample
and, on multivariable analysis, blacks and ES-Latinas were signifi-
cantly more likely to have experienced at least one privation than
whites (Table 4). Other correlates of at least one privation were Detroit
location, middle age (46 to 64) compared with younger ( 45) or
older ( 65) age, household income  $50,000, reduction in work
hours, and lack of substantial prescription drug coverage.
Overall, 15% of the 1,502 respondents reported decline in em-
ployment status since diagnosis, and 72% of these attributed the
decline to breast cancer. As depicted in Figure 1B, the overall propor-
tion reporting decline in employment status did not vary by race/
ethnicity (P  .23), but the proportion of those attributing the decline
at least partly to breast cancer did (P  .005). Eighteen percent re-
ported that their health insurance status was worse since diagnosis,
and of those, 73% felt this was at least somewhat because of breast
cancer. As depicted in Figure 1C, the overall proportion reporting that
their insurance status was worse did not vary by race/ethnicity (P 
.52), but the proportion of those attributing being worse off at least
partly to breast cancer did (P  .006).
Of the respondents, 741 reported that they worked for pay at
some time after diagnosis. As detailed in Table 5, in this subgroup,
60% reported that it was at least a little important to work to keep
health insurance, 53% to avoid changing jobs because of worry about
losing health insurance, and 27% to get a new job in order to get health
insurance. Of note, 25% of this subgroup reported that they would
look for a new job if they could be assured of comparable benefits
(48% of SS-Latinas, 30% ES-Latinas, 24% blacks, and 18% whites;
P  .001). Of those who worked at some time after diagnosis, 7% had
increased work hours to cover cancer-related expenses, 27% had de-
creased work hours because of cancer-related health issues, and 7%
believed they had been denied job opportunities because of cancer.
DISCUSSION
In this sample of long-term breast cancer survivors from two metro-
politan areas, one quarter perceived being worse off financially as a
result of their breast cancer. Even 4 years after diagnosis, 12% reported
having medical debt. Patients reported both economically motivated
treatment nonadherence and more general privations related to their
medical expenses. Minority patients were most vulnerable to priva-
tions and financial decline attributed to breast cancer, even after ad-
justment for income, education, and employment. To our knowledge,
this is the first study to report individual financial experiences in a
racially and ethnically diverse sample of patients with breast cancer
drawn from population-based registries.
Previous studies have suggested that patients with cancer face
substantial financial burden from treatment. Analysis of Medical Ex-
penditure Panel Survey data from 2001 to 2008 suggested that 13.4%
of patients with cancer spent  20% of income on out-of-pocket
Table 4. Multivariable Model of Reporting at Least One Major Privation
Because of Medical Expenses
Covariate
Privations (N  1,298)
OR 95% CI P
Site
Los Angeles (reference) 1.00
Detroit 1.59 1.03 to 2.45 .035
Age at diagnosis, years
 46 0.94 0.91 to 0.96  .001
46-55 3.40 1.63 to 7.12 .001




Black 2.62 1.58 to 4.33  .001
Latino, English speaking 2.17 1.15 to 4.09 .017
Latino, Spanish speaking 1.30 0.53 to 3.18 .559
Education
College graduate or greater 0.75 0.43 to 1.30 .298
Some college/technical school (reference) 1.00
High school graduate 1.18 0.68 to 2.06 .557
Less than high school 1.53 0.76 to 3.05 .231
Marital status
Married/partnered (reference) 1.00
Not married 1.01 0.66 to 1.56 .960
Household income
$50,000 (reference) 1.00
 $50,000 2.05 1.16 to 3.60 .013
Working at diagnosis
Not working (reference) 1.00
Part time 1.25 0.66 to 2.38 .489
Full time 1.13 0.68 to 1.86 .646
Reduction in work hours
No (reference) 1.00
Yes 2.00 1.20 to 3.33 .008
Prescription covered by health insurance
Completely (reference) 1.00
Mostly 1.57 0.84 to 2.91 .155
Partially 4.16 2.17 to 7.99  .001
Not covered 12.04 5.38 to 26.94  .001
Comorbidities
0 (reference) 1.00
1 1.05 0.67 to 1.63 .840
Stage of disease
3 1.23 0.55 to 2.76 .608
2 0.97 0.58 to 1.61 .894
1 (reference) 1.00
0 1.14 0.66 to 1.99 .639
Surgery
Lumpectomy (reference) 1.00
Mastectomy without reconstruction 0.66 0.32 to 1.37 .263
Mastectomy with reconstruction 0.94 0.47 to 1.91 .874
Chemotherapy
No (reference) 1.00
Yes 1.54 0.89 to 2.66 .119
Radiotherapy




Yes 1.74 0.77 to 3.91 .183
Abbreviation: OR, odds ratio.
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health care expenses, including insurance premiums. This burden
may translate into significant privations. In a national survey of 930
patients with cancer, 11% reported inability to pay for food, heat, or
housing because of the costs of cancer treatment.27 National Health
Interview Survey data from 2003 to 2006 suggested that 7.8% of cancer
survivors reported forgoing medical care because of cost, although it
could not define whether survivors were forgoing cancer care or elec-
tive services.28 Financial stress has also been shown to compromise the
quality of life in patients with cancer.29
We are aware of only one other survey of patients identified
through a population-based registry on this subject.15 That study
focused on colon cancer survivors treated with curative intent, closer
to their initial treatment than the long-term breast cancer survivors in
the current study. That study also revealed that patients with younger
age, minority race, and lower annual household income were more
likely to report treatment-related financial hardship. Together, these
studies suggest that there is an identifiable subgroup of patients with
cancer who are particularly vulnerable to financial distress.
Several studies were conducted to evaluate the out-of-pocket
expenses of patients with breast cancer treated one to two decades
ago.6,30,31 These older studies estimated the monthly out-of-pocket
costs for medical expenses incurred by women during chemother-
apy to be between $300 and $1,180 per month, and approximately
$500 per month by 1 year after diagnosis.32 The findings of the
current study reveal that median total out-of-pocket spending on
breast cancer expenses 4 years postdiagnosis was  $2,000, consis-
tent with a study that revealed that from 1987 to 2001 through
2005, the proportion of cancer costs funded by private insurance
increased and the out-of-pocket share decreased.33 Nevertheless, a
substantial minority reported worsening of financial status, and
certain subgroups—including those of minority race or ethnicity—
appeared particularly vulnerable.
Previous studies have also raised concerns about the effects of
cancer on employment, including reduction of income and loss of
employment-based insurance, which can in turn adversely affect fi-
nancial status.34 We found that many survivors reported ways in
which cancer influenced their subsequent employment experiences
and decisions; concerns about maintaining insurance and benefits
were particularly common.
This study has strengths that include its identification of a diverse
sample of patients treated in multiple settings through population-
based registries, its longitudinal design, and its detailed measures of
financial status and burden derived from the broader literature on
financial distress. However, a limitation of our study was that we did
not compare the experiences of patients in our sample to noncancer
control patients. Although we asked patients whether they believed
that decline in financial status and privations were attributable to their
breast cancer, it is possible that these attributions are inaccurate. Also,
as in any survey study, bias may have been introduced by nonresponse.
Although the response rate to each of our surveys was high compared
with other survey studies of patients with cancer,35 there was attrition
in the sample at each step in the longitudinal evaluation, and it is
possible that respondents differed meaningfully from those who did
not respond. To minimize the impact of nonresponse bias, we em-
ployed complex survey weights. Finally, the study was located in two
large metropolitan areas, which may limit the generalizability of the
findings, particularly to more rural areas and those in which access to
Medicaid differs from that in California and Michigan at the time of
the study.
Despite these limitations, our findings suggest that a substantial
proportion of breast cancer survivors perceive a negative financial
impact from diagnosis and treatment, and they experience a variety of
privations. Racial and ethnic minorities appeared more vulnerable
than whites. Unfortunately, communication between patients and
physicians regarding financial concerns is suboptimal.36-41 The cur-
rent findings should motivate increased efforts to ensure communi-
cation between patients and providers regarding the financial
implications of cancer diagnosis and treatment decisions. Further
research should consider how changes since the time of our study,
including the availability of lower-cost generic equivalents for com-
monly prescribed endocrine therapies, impending changes in Medic-
aid eligibility mandated by the Affordable Care Act, and the creation of
a federal Consumer Financial Protection Bureau to regulate consumer
credit more tightly, may have modified the experiences of patients
currently being diagnosed, as compared with those reported by the
patients in our study. Additional research is also important to further
define the long-term financial experiences of patients with other types
of cancer, whose experiences may differ from those in our sample for
various reasons (including differences in treatments, prognosis, and
insurance eligibility), as well as the predictors for vulnerability to
financial decline and privations in those settings, to allow for the
rational targeting of interventions and support.
Table 5. Employment Experiences Reported by Breast Cancer Survivors Who
























health insurance 53 65 59 59 47 .07
Get a new job to
get health
insurance 27 54 32 36 16  .001
Reporting …
Would look for a
new job if could
be assured of
comparable














cancer 7 7 9 5 7 .76
Jagsi et al
1274 © 2014 by American Society of Clinical Oncology JOURNAL OF CLINICAL ONCOLOGY
Although we are deservedly proud of advances in our ability to
cure an increasing proportion of patients diagnosed with breast can-
cer, we must ensure that we do not leave them in financial ruin as a
result of our efforts. Providers, researchers, and policymakers alike
must make dedicated efforts to reduce the cost of medical care in order
to help prevent the lasting deleterious impact on the financial well-
being of patients of the sort observed in this study.
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Appendix
Patients with breast cancer identified
(N =  3,252)
Excluded
   Too ill
   Denied having cancer
   Physicians refused to allow patient contact







   Could not be contacted




Analytic exclusions (“other” racial category) (n = 34)
Could not be merged with SEER data (n = 22)
Sent surveys
(n =  3,133)
Final analytic sample
(n =  1,502)
Completed a baseline survey
(n =  2,290, response rate: 73%)
Completed a follow-up survey
approximately 4 years after diagnosis
(n =  1,536, response rate: 68%)
Fig A1. This figure depicts the evolution of the analytic sample of women diagnosed with breast cancer in metropolitan Los Angeles and Detroit. Cases were initially
selected on the basis of rapid case ascertainment, which lacks the level of quality control that is ultimately used to determine inclusion in the SEER registry. Certain
cases that were initially identified and surveyed were ultimately excluded from SEER because they were no longer considered to be reportable cases after quality
control; as shown above, 22 cases could not be merged to SEER and were therefore excluded from the sample.
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